Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Lyme Disease Treatment Market Expected to Garner $1,636.6 Million by 2031, Growing at 8.4% CAGR from 2022-2031 [200-Pages] | Commended by Research Dive

This image opens in the lightbox

News provided by

Research Dive

06 Mar, 2023, 11:59 GMT

Share this article

Share toX

Share this article

Share toX

The Lyme disease treatment market is expected to grow by 2031 due to the rising number of Lyme disease cases. The medication sub-segment is predicted to be the most lucrative. The market in North America is expected to be the most dominant.

NEW YORK, March 6, 2023 /PRNewswire/ -- Research Dive has added a new report to its offering titled, "Lyme Disease Treatment Market by Treatment Type (Medication and Tick Removal), Administration Route (Oral, Injectable, and Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2022-2031".

As per the report, the global Lyme disease treatment market is predicted to grow at a stable CAGR of 8.4% in the 2022-2031 timeframe, thereby garnering $1,636.6 million by 2031.

Dynamics of the Market

Drivers: Lyme disease is one of the most prevalent vector-borne diseases in the world and its growing incidence is expected to be the primary growth driver of the Lyme disease treatment market. Along with this, the growing threat of tick-borne diseases is anticipated to push the market further.

Opportunities: Increasing research and development to develop a full-proof Lyme disease treatment is predicted to offer numerous growth opportunities to the market in the forecast period. Additionally, the growing prevalence of Lyme disease is expected to propel the market further.

Restraints: Misdiagnosis of Lyme disease, however, may dampen the growth rate of the Lyme disease treatment market.

To get access to the All-Inclusive PDF Sample of the Lyme Disease Treatment Market Click Here!

Impact of Covid-19 on the Market

The Covid-19 pandemic, since its outbreak, has been disastrous for industries and businesses across the globe. The Lyme disease treatment market is no exception to this phenomenon. In fact, the Lyme disease treatment market faced a direct impact of the pandemic as all the healthcare infrastructure and medical staff was focused on treating COVID-19 patients and curbing the spread of the pandemic. Also, the medical research world focused its energies on developing vaccines for the COVID-19 virus which put Lyme disease treatment research on the back-burner. All these factors led to a decline in the growth rate of the market.

Segments of the Market

The report has divided the Lyme disease treatment market into different segments based on treatment type, administration route, distribution channel, and region.

  • By treatment type, the medication sub-segment is predicted to have the most dominant market share and generate a revenue of $1,116.1 million by 2031. Prominent use of antibacterial medicines and antibiotics such as Doxycycline and amoxicillin is expected to help in the growth of this sub-segment.
  • By administration route, the oral sub-segment is anticipated to become the most lucrative sub-segment and register a revenue of $784.2 million by 2031. Oral administration is the most opted route since there is high patient adherence and is easy to administer. Hence, the sub-segment is expected to flourish in the forecast period due to the increasing adoption of the oral administration route.
  • By distribution channel, the hospital pharmacies sub-segment is predicted to be the most profitable sub-segment and surpass a revenue of $865.6 million by 2031. Hospital pharmacists form an important unit of the healthcare community as they can deliver their knowledge of medication to other healthcare members and staff. The crucial role played by hospital pharmacies is, hence, expected to drive the sub-segment forward.
  • By regional analysis, the Lyme disease treatment market in the North America is expected to be the most dominant and is projected to grow with a CAGR of 8.0% in the forecast period. The climatic conditions of this region have led to a massive surge in the number of Lyme disease cases which is estimated to be the primary growth driver of the market in the forecast period.

Schedule a call with an Analyst to get Post COVID-19 Impact on Lyme Disease Treatment Market

Significant Market Players

The significant market players of the Lyme disease treatment market are

  • Galaxo SmithKline Plc
  • Sun Pharmaceuticals Industries, Inc.
  • Perrigo Company plc
  • Pfizer, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Chartwell Pharmaceuticals
  • Novartis AG
  • Orion Corporation
  • Almirall
  • LLC
  • Mayne Pharma

These key market players are developing different strategies like product development, merger and acquisitions, partnerships and collaborations to gain a leading position in the market.

For instance, in August 2022, Pfizer Inc., a leading pharmaceutical industry, announced that it was partnering with Valneva SE, a leading biotech company, in order to commence the Phase 3 clinical study of Vaccine Against Lyme for Outdoor Recreationists (VALOR) program and test the efficacy of the vaccine candidate, VLA15. This partnership is expected to be a path-breaking step in the treatment of Lyme disease.

This report also summarizes many crucial aspects of the market including SWOT analysis, latest strategic developments, financial performance of the key players, and product portfolio.

Request Customization of Lyme Disease Treatment Market Report & Avail of Amazing Discount

More about Lyme Disease Treatment Market:

  • Lyme Disease Treatment: An Approach of Killing Harmful Bacteria with Effective Antibiotics
  • Global Lyme Disease Treatment Market to Rise at a CAGR of 8.4% and Surpass $1,636.6 Million by 2031, Owing to the Rising Cases of Lyme Diseases Worldwide

Some Trending Article Links:

  • The Global Gene Synthesis Market Size was $1,110,000 thousand in 2021 and is predicted to grow with a CAGR of 18.4%, by generating a revenue of $5,984,016.7 thousand by 2031
  • The Global Plant Tissue Culture Market Size was $1,220 million in 2021 and is predicted to grow with a CAGR of 6.4%, by generating a revenue of $2,202.9 million by 2031
  • The Global Urinary Tract Infection Testing Market Size was $574 million in 2021 and is predicted to expand at a CAGR of 6.2%, generating revenue of $1,027.4 million by 2031

About Research Dive

Research Dive is a market research firm based in Pune, India. Maintaining the integrity and authenticity of the services, the firm provides the services that are solely based on its exclusive data model, compelled by the 360-degree research methodology, which guarantees comprehensive and accurate analysis. With an unprecedented access to several paid data resources, team of expert researchers, and strict work ethic, the firm offers insights that are extremely precise and reliable. Scrutinizing relevant news releases, government publications, decades of trade data, and technical & white papers, Research dive deliver the required services to its clients well within the required timeframe. Its expertise is focused on examining niche markets, targeting its major driving factors, and spotting threatening hindrances. Complementarily, it also has a seamless collaboration with the major industry aficionado that further offers its research an edge.

Contact:
Mr. Abhishek Paliwal
Research Dive
30 Wall St. 8th Floor, New York NY 10005
(P) +91-(788)-802-9103 (India)
+1-(917)-444-1262 (US)
Toll Free: 1-888-961-4454
E-mail: support@researchdive.com 
Website: https://www.researchdive.com
Blog: https://www.researchdive.com/blog/
LinkedIn: https://www.linkedin.com/company/research-dive/
Twitter: https://twitter.com/ResearchDive
Facebook: https://www.facebook.com/Research-Dive-1385542314927521

Logo: https://mma.prnewswire.com/media/997523/Research_Dive_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.